ReviewTherapeutic innovation & regulatory science2025
Real-World Evidence in FDA Approvals for Labeling Expansion of Small Molecules and Biologics.
Review in Therapeutic innovation & regulatory science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReal-world evidence (RWE) can support the evaluation of safety and efficacy for medical products, but its extent of use in labeling expansion submissions remains unclear. This study aimed to characterize the RWE used in labeling expansion or likely used, as identified through literature search, for drugs and biologics.
methodsWe identified RWE used in FDA-approved labeling expansion for drug and biologic supplemental applications from January 2022 to May 2024 (Drugs@FDA), using FDA prescribing information and review documents. We also searched ClinicalTrials.gov and PubMed to identify RWE not included in the FDA approval letter and labeling but could have been incorporated into submissions by sponsors. Characteristics of the RWE were extracted and summarized.
resultsAmong 218 labeling expansions granted, RWE was found in FDA documents for 3 approvals and elsewhere for 52 approvals. The proportion of approvals with RWE was 23.3%, 27.7%, and 23.7% in 2022, 2023, and 2024, respectively. RWE was most commonly found in submissions for oncology (43.6%), infection (9.1%), and dermatology (7.3%). Greater use of RWE was identified in submissions for drugs (69.1%) and to expand indications (78.2%). RWE came from 88 studies, with 48.9% addressing both safety and efficacy. Most of the RWE studies were retrospective (65.9%), employed a cohort study design (87.5%), and used electronic health records (EHR) data (75.0%).
conclusionWe observed limited RWE use in granted labeling expansion, and the reason is unclear due to incomplete FDA documentation of supplemental approvals-RWE may not have been submitted, may have been submitted but determined by FDA to be of limited use, may have contributed substantively to the supplemental approval, or some combination of these across submissions. Improving accessibility and transparency in RWE's acceptability within review documents can enhance our understanding of the extent and quality of RWE used for labeling expansion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.